BRCA2 and breast cancer: After adjusting for other prognostic factors and therapy, Jonasson et al. [47] demonstrated that patients with ER-positive BC with a BRCA2 mutation had worse prognosis than did patients with ER-negative BC(HR = 1.61, 95% CI 1.11–2.35, P = 0.01).